SBIA
NBIX icon

Sheaff Brock Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$290K Buy
2,619
+120
+5% +$15.2K 0.03% 337
2024
Q4 		$341K Buy
2,499
+261
+12% +$32.3K 0.03% 312
2024
Q3 		$258K Buy
2,238
+268
+14% +$36.7K 0.02% 354
2024
Q2 		$271K Buy
1,970
+92
+5% +$12.6K 0.03% 338
2024
Q1 		$259K Buy
1,878
+197
+12% +$26.9K 0.02% 384
2023
Q4 		$221K Buy
+1,681
New +$193K 0.02% 401
2023
Q1 		– Sell
-1,721
Closed -$206K – 535
2022
Q4 		$206K Buy
+1,721
New +$202K 0.02% 408

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sheaff Brock Investment Advisors's NBIX Position: Q1 2025 in Review

Sheaff Brock Investment Advisors increased its Neurocrine Biosciences (NBIX) stake by 4.8% in Q1 2025, buying an estimated $15.2K and bringing the position to 2,619 shares worth $290K. The position accounts for 0.03% of the portfolio, ranked #337.

Sheaff Brock Investment Advisors first reported a position in NBIX in Q4 2022 and has held it in 7 quarters since. The position peaked at $341K in Q4 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Sheaff Brock Investment Advisors held 2,619 shares of Neurocrine Biosciences worth $290K as of Q1 2025.
  • Sheaff Brock Investment Advisors bought 120 Neurocrine Biosciences shares in Q1 2025, an estimated $15.2K.
  • Neurocrine Biosciences made up 0.03% of Sheaff Brock Investment Advisors's portfolio in Q1 2025, its #337 holding.
  • Sheaff Brock Investment Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 7 quarters since.
  • Sheaff Brock Investment Advisors's Neurocrine Biosciences position peaked at $341K in Q4 2024.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2025, filed 7 May 2025.